Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$129.9MBeat by $11.0M
EPS$0.11Beat by $0.05
Revenue estimate$118.9M
EPS estimate$0.06
“Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three indications. With our investment in expanding our dermatology sales force and initiatives designed to simplify patient access, we are well positioned to drive continued growth and momentum through the second half of 2026. During the quarter, we also made significant progress in advancing our pipeline, highlighted by the FDA acceptance of our sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis and completion of enrollment in our Phase 2 vitiligo study.”
Frank Watanabe

Next report

Oct 27, 2026 (in a month)
Revenue estimate$141.7M
EPS estimate$0.17

Financials

Q2 2026

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M—
CapEx$158.0K+103%
Free cash flow$12.5M—

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$3.29B+59.9%
Enterprise value$3.37B+60.8%
P/S7.1×-0.7×

Profitability

See full
Gross margin91.1%+2.0pp

Returns & leverage

See full
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Segments

By segment

See full
Reportable Segment$129.9M+59.3%

FAQ

When did Arcutis Biotherapeutics, Inc. report Q2 2026 earnings?
Arcutis Biotherapeutics, Inc. (ARQT) reported Q2 2026 earnings on August 5, 2026 after market close.
What were Arcutis Biotherapeutics, Inc.'s Q2 2026 revenue and EPS?
Arcutis Biotherapeutics, Inc. reported revenue of $129.9M and eps of $0.11 for Q2 2026.
Did Arcutis Biotherapeutics, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $118.9M by $11.0M. EPS beat the consensus estimate of $0.06 by $0.05.
How did Arcutis Biotherapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 59.3% from $81.5M a year earlier.
Where can I find Arcutis Biotherapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001787306-26-000049) and the 10-Q periodic report (0001787306-26-000051) directly on SEC EDGAR. The filing index links above go to sec.gov.